Rough Meeting Ahead Between Nektar Therapeutics and FDA Advisory Committee

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Jan 13, 2020 at 11:52 PM.

  1. cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,746
    Likes Received:
    3
    via Things aren't looking great for oxycodegol, a potential new pain drug that has been in Nektar Therapeutics' (NASDAQ: NKTR) late-stage pipeline for a long time. The FDA will discuss the slow-acting opioid's benefits in light of its risks with a panel of independent experts on Jan. 14, 2020, and recently released briefing documents prepared for the advisory committee aren't too encouraging.

    article source